All In Biotech

Drug Trial Radar · NCT07013747

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne

A Phase 1/2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Participants With Mild Acne

Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

228

Planned (sponsor's estimate)

Start

Jul 3, 2025

Primary completion

Jun 19, 2029

Study completion Mar 13, 2030

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jun 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the VBE00009 study is to evaluate the safety, efficacy and immunogenicity of 2 administrations of the Acne mRNA vaccine candidate at single dose level in participants aged 18 to 45 years with mild acne. This study will consist of a Core Study followed by an optional Long-Term Extension (LTE). Core Study will include a Sentinel Cohort and a Main Cohort, with the Sentinel Cohort assessing the safety in a stepwise manner. If the participants consent to the LTE, they will be followed up for an additional 30 months after the last planned visit in the Core Study, to assess the long term effects of the vaccine.

Conditions

  • Acne

Interventions

  • Acne mRNA vaccineBiological

    Pharmaceutical form: suspension for injection Route of administration: intramuscular

  • PlaceboOther

    Pharmaceutical form: liquid solution for injection Route of administration: intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with unsolicited systemic adverse events (AEs)Time frame: In 30 minutes after each administration
  2. Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with solicited injection site and systemic reactionsTime frame: Up to 7 days after each administration
  3. Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with unsolicited AEs reportedTime frame: Up to 28 days after each administration
  4. Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with medically attended adverse events (MAAEs)Time frame: Up to 6 months after each administration
  5. Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with AEs of special interest (AESIs)Time frame: Up to 6 months after each administration
  6. Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with serious AEs (SAEs)Time frame: Up to 6 months after each administration
  7. Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with out-of-range biological test resultsTime frame: Through 7 days after administration (Day 08)
  8. Core Study - Main Cohort Arm 1 and 2: Percentage change from baseline (Day 01) in the number of inflammatory acne lesions on faceTime frame: At 2 months post last administration
  9. Core Study - Main Cohort Arm 1 and 2: Percentage change from baseline (Day 01) in the number of non-inflammatory acne lesions on faceTime frame: At 2 months post last administration
  10. Long-Term Extension - Sentinel and Main Cohort Arm 1 and 2: Number of participants with serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: Up to 38 months after first administration

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Encino Research Center- Site Number : 8400008

    Encino, California · Recruiting

  • Moore Clinical Research - Brandon- Site Number : 8400007

    Brandon, Florida · Recruiting

  • Encore Research Group-Jacksonville Center for Clinical Research- Site Number : 8400006

    Jacksonville, Florida · Recruiting

  • DelRicht Research- Site Number : 8400003

    New Orleans, Louisiana · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.